Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 118

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 118
---
5 to
regain compliance with the Stockholders’ Equity Requirement.

As a result of the Company’s closing of a
private placement offering for gross proceeds of approximately $4.9 million on October 15, 2025, the Company believes it has
regained compliance with the minimum $2.5 million Stockholders’ Equity Requirement for continued listing. Nasdaq will continue
to monitor the Company’s ongoing compliance with the Stockholders’ Equity Requirement and, if at the time of its next
periodic report the Company does not evidence compliance, it may be subject to delisting.

If our common stock ceases to be listed for trading
on the Nasdaq Capital Market, we would expect that our common stock would be traded on one of the three tiered marketplaces of the OTC
Markets Group. If Nasdaq were to delist our common stock, it would be more difficult for our stockholders to dispose of our common stock
and more difficult to obtain accurate price quotations on our common stock. Our ability to issue additional securities for financing or
other purposes, or otherwise to arrange for any financing we may need in the future, may also be materially and adversely affected if
our common stock or warrants are not listed on a national securities exchange.

Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information 

Rule 10b5-1 Trading Plans

None of the Company’s directors or officers
adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s
fiscal quarter ended September 30, 2025.

29

Item 6. Exhibits

    Exhibit Number
     
    Description
  
    3.1
     
    Fourth Amended and Restated Certificate of Incorporation of the Company, as amended [Restated for SEC filing purposes only] (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed on March 31, 2025)
  
    3.2
     
    Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-1 (File No. 333-214724